PemolineCNS stimulant, indirect monoamine agonist CAS# 2152-34-3 |
2D Structure
- Pralatrexate
Catalog No.:BCC2304
CAS No.:146464-95-1
- Pyrimethamine
Catalog No.:BCC2307
CAS No.:58-14-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 2152-34-3 | SDF | Download SDF |
PubChem ID | 4723 | Appearance | Powder |
Formula | C9H8N2O2 | M.Wt | 176.17 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Phenoxazole, Phenylisohydantoin | ||
Solubility | Soluble to 10 mM in ethanol with gentle warming | ||
Chemical Name | 2-amino-5-phenyl-1,3-oxazol-4-one | ||
SMILES | C1=CC=C(C=C1)C2C(=O)N=C(O2)N | ||
Standard InChIKey | NRNCYVBFPDDJNE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Long-acting central stimulant that induces self-injurious behavior in rats. Acts as an indirect monoamine agonist. |
Pemoline Dilution Calculator
Pemoline Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.6763 mL | 28.3817 mL | 56.7634 mL | 113.5267 mL | 141.9084 mL |
5 mM | 1.1353 mL | 5.6763 mL | 11.3527 mL | 22.7053 mL | 28.3817 mL |
10 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL | 11.3527 mL | 14.1908 mL |
50 mM | 0.1135 mL | 0.5676 mL | 1.1353 mL | 2.2705 mL | 2.8382 mL |
100 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.1353 mL | 1.4191 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- BMS 493
Catalog No.:BCC7697
CAS No.:215030-90-3
- Methyl 2,6-dihydroxybenzoate
Catalog No.:BCN3563
CAS No.:2150-45-0
- Protocatechuic acid methyl ester
Catalog No.:BCN3542
CAS No.:2150-43-8
- 7,3',4'-Trihydroxyflavone
Catalog No.:BCN4674
CAS No.:2150-11-0
- Bruceine D
Catalog No.:BCN2894
CAS No.:21499-66-1
- Agrimonolide
Catalog No.:BCN4925
CAS No.:21499-24-1
- H-Arg(NO2)-OH
Catalog No.:BCC2864
CAS No.:2149-70-4
- 2-Deacetyltaxachitriene A
Catalog No.:BCN7415
CAS No.:214769-96-7
- AMT hydrochloride
Catalog No.:BCC6823
CAS No.:21463-31-0
- (+)-Syringaresinol
Catalog No.:BCN7496
CAS No.:21453-69-0
- 1400W dihydrochloride
Catalog No.:BCC7057
CAS No.:214358-33-5
- 16alpha-Hydroxybauerenol
Catalog No.:BCN7724
CAS No.:214351-30-1
- Betamethasone Valerate
Catalog No.:BCC3736
CAS No.:2152-44-5
- BMS 753
Catalog No.:BCC6031
CAS No.:215307-86-1
- Senampeline F
Catalog No.:BCN7804
CAS No.:71075-43-9
- Mianserin HCl
Catalog No.:BCC1114
CAS No.:21535-47-7
- SU 5402
Catalog No.:BCC1970
CAS No.:215543-92-3
- Sodium Dichloroacetate
Catalog No.:BCN2951
CAS No.:2156-56-1
- 23-deoxojessic acid
Catalog No.:BCN4926
CAS No.:215609-93-1
- Cyclocephaloside II
Catalog No.:BCC8310
CAS No.:215776-78-6
- SB269652
Catalog No.:BCC8052
CAS No.:215802-15-6
- SB-277011
Catalog No.:BCC1928
CAS No.:215803-78-4
- Bruceine E
Catalog No.:BCN7619
CAS No.:21586-90-3
- CX 546
Catalog No.:BCC7532
CAS No.:215923-54-9
The pemoline model of self-injurious behaviour.[Pubmed:22231812]
Methods Mol Biol. 2012;829:155-63.
Traditional models of neuropsychiatric disorders consist of attempts to replicate the broad spectrum of behavioural and neurochemical sequelae that characterize a specific disorder. However, these disorders comprise complex constellations of symptoms, including emotional instability, perseverative thoughts, and aberrant behaviours. Close examination often reveals heterogeneity of symptom expression within patient groups and homogeneity in expression of specific symptoms across diagnostic categories. Accordingly, it may not be possible to model the entire spectrum of characteristics for any one of these disorders in any single animal model. A focus on one or more specific behavioural characteristics (e.g. self-injury) may be a more fruitful strategy. Development of behaviourally focused models yields increased understanding of the genetic basis and biochemical abnormalities that underlie specific psychiatric dysfunctions. Furthermore, by revealing pathophysiology that underlies specific disease characteristics, behaviourally focused models improve translational power and help to identify targets for effective pharmacotherapies. One such behaviourally focused animal model is the Pemoline model of self-injurious behaviour.
Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole.[Pubmed:24574157]
Drug Test Anal. 2014 Oct;6(10):1049-54.
Levamisole is an anti-helminthic drug and gained forensic interest after it was found that it was used as a cocaine adulterant. A liquid chromatography-mass spectrometry (LC-MS) method for the determination of levamisole and its metabolite aminorex in human plasma is described. Selectivity is given; calibration curves were linear within a calibration range of 1 ng/mL-500 ng/mL. Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively. Precision data was in accordance with the GTFCh guidelines. The validated method was successfully applied to study the pharmacokinetics of levamisole after administration of 100 mg of levamisole orally. Levamisole could be detected up to 36 h after ingestion in serum, while aminorex never exceeded the LOQ. A one-compartment model best described levamisole pharmacokinetics. The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t (1/2) = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h. Levamisole could be quantified in 42.5% of cocaine--positive plasma samples (2.2 to 224 ng/mL). Aminorex was positive in only 11.3% of the cases; however, it was never found higher than the LOQ. Pemoline, another stimulant detected in horse urine samples after administration of levamisole, was not found either in serum or in urine of this pharmacokinetic study. In post-mortem cases, levamisole and aminorex could be detected in femoral blood and the urine of cocaine users. Pemoline was not detected.
Self-injurious behavior vs. nonsuicidal self-injury: the CNS stimulant pemoline as a model of self-destructive behavior.[Pubmed:22343062]
Crisis. 2012 Jan 1;33(2):106-12.
BACKGROUND: Historically, the field of self-injury has distinguished between the behaviors exhibited among individuals with a developmental disability (self-injurious behaviors; SIB) and those present within a normative population (nonsuicidal self-injury; NSSI),which typically result as a response to perceived stress. More recently, however, conclusions about NSSI have been drawn from lines of animal research aimed at examining the neurobiological mechanisms of SIB. Despite some functional similarity between SIB and NSSI, no empirical investigation has provided precedent for the application of SIB-targeted animal research as justification for pharmacological interventions in populations demonstrating NSSI. AIMS: The present study examined this question directly, by simulating an animal model of SIB in rodents injected with Pemoline and systematically manipulating stress conditions in order to monitor rates of self-injury. METHODS: Sham controls and experimental animals injected with Pemoline (200 mg/kg) were assigned to either a low stress (discriminated positive reinforcement) or high stress (discriminated avoidance) group and compared on the dependent measures of self-inflicted injury prevalence and severity. RESULTS: The manipulation of stress conditions did not impact the rate of self-injury demonstrated by the rats. The results do not support a model of stress-induced SIB in rodents. CONCLUSIONS: Current findings provide evidence for caution in the development of pharmacotherapies of NSSI in human populations based on CNS stimulant models. Theoretical implications are discussed with respect to antecedent factors such as preinjury arousal level and environmental stress.
Pemoline (2-amino-5-phenyl-1,3-oxazol-4-one)-induced self-injurious behavior: a rodent model of pharmacotherapeutic efficacy.[Pubmed:17925479]
J Pharmacol Exp Ther. 2008 Jan;324(1):214-23.
Self-injury is a devastating, maladaptive behavior disorder that is common in developmental disabilities and is comorbid with numerous psychiatric disorders. Examples of self-injurious behavior (SIB) include head-banging, self-biting, and self-punching. The neurochemical basis of SIB is unknown; however, many different classes of drugs are prescribed (e.g., neuroleptics, atypical neuroleptics, anti-epileptics, opioid antagonists) to reduce these behaviors. These drugs have all shown clinically significant but limited efficacy in patient populations, and no class of drug is effective for all patients. The development and characterization of a valid animal model could provide important information regarding the neurochemical basis of SIB and could be used to screen potential new pharmacotherapies. In one model of SIB, high doses of Pemoline (2-amino-5-phenyl-1,3-oxazol-4-one) are administered to rats. Using this model, we evaluated the effectiveness of three drugs (risperidone, valproate, and topiramate) that reduce SIB in humans. We also screened the potential effectiveness of tramadol, a drug that decreases stereotyped and compulsive behaviors but has not been assessed in human self-injurers. We found that risperidone, valproate, and topiramate each significantly attenuate Pemoline-induced SIB, whereas tramadol does not. These findings suggest that the Pemoline model of SIB has predictive validity across a range of drug classes and implicate important potential neurochemical mechanisms that may contribute to the behavior disorder. The findings also indicate that tramadol may not be an effective pharmacotherapy for SIB.
Self-injurious behaviour: a comparison of caffeine and pemoline models in rats.[Pubmed:15582667]
Pharmacol Biochem Behav. 2004 Dec;79(4):587-98.
Self-injurious behaviour (SIB) is a debilitating behaviour disorder that can have life-threatening consequences. It is often exhibited in intellectually handicapped and autistic populations, and it has been modeled with pharmacological manipulations in animals. We have characterized the induction of SIB using high doses of caffeine and Pemoline in rats. Caffeine only produced very mild SIB in a small proportion of the rats, when administered repeatedly at very high doses (140-185 mg/kg/day). All the caffeine-treated rats showed profound signs of caffeine-toxicity at these doses, and lower doses did not induce any self-injury. On the other hand, Pemoline was effective across a range of doses (100-300 mg/kg/day), including doses that did not produce overt signs of toxicity (100-200 mg/kg/day). The topography of the tissue injury sites (tail vs. paws and ventrum) differed between caffeine and Pemoline treatments, and across doses of Pemoline. The speed of onset, the incidence, and the severity of SIB occurred in a dose-orderly manner across the Pemoline doses, and there was substantial individual variability in the induction of SIB when a moderately high dose (200 mg/kg/day) was used. These individual differences in vulnerability to self-injure are reminiscent of the fact that some humans with specific neurobiological disorders express SIB and some individuals with those same disorders do not. Accordingly, the Pemoline model of SIB may be useful to investigate the neurobiological basis of factors that contribute to etiology of SIB.
Pharmacologic control of pemoline induced self-injurious behavior in rats.[Pubmed:6213967]
Pharmacol Biochem Behav. 1982 Jun;16(6):957-63.
Administration of oral Pemoline produces long lasting amphetamine-type stereotyped behavior and persistent self-biting behavior in rats. The effects of haloperidol, pimozide, diazepam, and serotonin depletion by pretreatment with p-chlorophenylalanine (PCPA) or chronic pretreatment with p-chloroamphetamine (PCA) on abnormal behavior produced by Pemoline were studied. Diazepam consistently increased the duration of stereotyped behavior. It also reduced licking/biting and self-biting but the latter effects were not consistent. Pretreatment with PCA had negligible effects on stereotyped behavior. Pretreatment with PCPA dramatically increased locomotion and rearing without affecting the other components of stereotypy--stereotyped head movements, licking/biting, and self-biting. Haloperidol (0.2 and 0.3 mg/kg) produced a dose related normalization of Pemoline induced behaviors, including elimination of self-biting. Pimozide (0.5, 0.8 and 1.3 mg/kg) had little or no effect on behaviors such as locomotions, rears, licking/biting, or stereotyped head movements but eliminated self-biting at 1.3 mg/kg. These data suggest that Pemoline, like amphetamine, produces stereotyped behavior through central dopaminergic mechanisms. Dopaminergic mechanisms also appear to be involved in Pemoline induced self-biting. Pemoline is apparently pharmacologically and behaviorally very similar to amphetamine. Pemoline may provide a useful animal model for syndromes characterized by self-injurious behavior and other repetitive behaviors.